TY - JOUR
T1 - What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study
AU - Coates, Laura C.
AU - Robinson, Danielle E.
AU - Orbai, Ana Maria
AU - Kiltz, Uta
AU - Leung, Ying Ying
AU - Palominos, Penelope
AU - Cañete, Juan D.
AU - Scrivo, Rossana
AU - Balanescu, Andra
AU - Dernis, Emmanuelle
AU - Meisalu, Sandra
AU - Ruyssen-Witrand, Adeline
AU - Eder, Lihi
AU - De Wit, Maarten
AU - Smolen, Josef S.
AU - Lubrano, Ennio
AU - Gossec, Laure
N1 - Funding Information:
Funding: This study was supported by an unrestricted research grant from Pfizer. Pfizer did not have any input into the analysis or submission for publication. LCC is funded by a National Institute of Health Research Clinician Scientist Award. The work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Publisher Copyright:
© 2021 Medical Information Center. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Objective. In PsA, the treatment objective is remission or low disease activity (LDA), but patients' perception of remission is poorly studied. This analysis aimed to identify factors associated with patient-defined remission. Methods. This analysis uses ReFlaP data, an international PsA study, with remission defined as 'At this time, is your psoriatic arthritis in remission, if this means: You feel your disease is as good as gone?'. Variables associated with, first, patient-defined remission and, second, LDA were identified using multivariable logistic regression and principal component analysis (PCA) to explore correlated variables. Results. Of 424 patients (50.2% male, mean age 52 years) with established disease, 94 (22.2%) reported themselves as being in remission and 191 (45.0%) as LDA alone. In multivariable analysis pain, psoriasis, impact of disease, physician opinion of symptoms from joint damage and Groll comorbidity index were independent predictors of remission. For LDA, results were similar. Using PCA, variance explained was 74% by five components for men and 80% by six components for women. The key component from PCA for remission was, for both sex, disease impact (Psoriatic Arthritis Impact of Disease, pain and HAQ) explaining 22.2-27.5% of variance. Other factors included musculoskeletal disease activity, chronicity/joint damage, psoriasis, enthesitis and CRP. For LDA, similar factors were identified but the variance explained was lower (64-68%). Conclusion. Many factors impact on patients' opinion of remission, dominated by disease impact. Disease activity in multiple domains, chronicity/age, comorbidities and symptoms due to other conditions contribute to a robust model highlighting that patient-defined remission is multifaceted.
AB - Objective. In PsA, the treatment objective is remission or low disease activity (LDA), but patients' perception of remission is poorly studied. This analysis aimed to identify factors associated with patient-defined remission. Methods. This analysis uses ReFlaP data, an international PsA study, with remission defined as 'At this time, is your psoriatic arthritis in remission, if this means: You feel your disease is as good as gone?'. Variables associated with, first, patient-defined remission and, second, LDA were identified using multivariable logistic regression and principal component analysis (PCA) to explore correlated variables. Results. Of 424 patients (50.2% male, mean age 52 years) with established disease, 94 (22.2%) reported themselves as being in remission and 191 (45.0%) as LDA alone. In multivariable analysis pain, psoriasis, impact of disease, physician opinion of symptoms from joint damage and Groll comorbidity index were independent predictors of remission. For LDA, results were similar. Using PCA, variance explained was 74% by five components for men and 80% by six components for women. The key component from PCA for remission was, for both sex, disease impact (Psoriatic Arthritis Impact of Disease, pain and HAQ) explaining 22.2-27.5% of variance. Other factors included musculoskeletal disease activity, chronicity/joint damage, psoriasis, enthesitis and CRP. For LDA, similar factors were identified but the variance explained was lower (64-68%). Conclusion. Many factors impact on patients' opinion of remission, dominated by disease impact. Disease activity in multiple domains, chronicity/age, comorbidities and symptoms due to other conditions contribute to a robust model highlighting that patient-defined remission is multifaceted.
KW - assessment
KW - disease activity
KW - low disease activity
KW - outcome measures
KW - psoriatic arthritis
KW - remission
KW - spondyloarthritis
KW - treat-to-target
UR - http://www.scopus.com/inward/record.url?scp=85121939739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121939739&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keab220
DO - 10.1093/rheumatology/keab220
M3 - Article
C2 - 33751029
AN - SCOPUS:85121939739
SN - 1310-0505
VL - 60
SP - 5292
EP - 5299
JO - Revmatologiia (Bulgaria)
JF - Revmatologiia (Bulgaria)
IS - 11
ER -